Publication

Toxoplasmosis in Transplant Recipients, Europe, 2010-2014

Journal Paper/Review - Aug 1, 2018

Units
Keywords
PubMed
Doi
Link
Contact

Citation
Robert-Gangneux F, Meroni V, Dupont D, Botterel F, Garcia J, Brenier-Pinchart M, Accoceberry I, Akan H, Abbate I, Boggian K, Bruschi F, Carratala J, David M, Drgona L, Djurković-Djaković O, Farinas M, Genco F, Gkrania-Klotsas E, Groll A, Guy E, Hirzel C, Khanna N, Kurt Ö, Junie L, Lazzarotto T, Len O, Mueller N, Munoz P, Pana Z, Roilides E, Stajner T, Van Delden C, Villena I, Pelloux H, Manuel O. Toxoplasmosis in Transplant Recipients, Europe, 2010-2014. Emerging Infect Dis 2018; 24:1497-1504.
Project
Type
Journal Paper/Review (English)
Journal
Emerging Infect Dis 2018; 24
Publication Date
Aug 1, 2018
Issn Print
Issn Electronic
1080-6059
Pages
1497-1504
Publisher
Brief description/objective

Transplantation activity is increasing, leading to a growing number of patients at risk for toxoplasmosis. We reviewed toxoplasmosis prevention practices, prevalence, and outcomes for hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT; heart, kidney, or liver) patients in Europe. We collected electronic data on the transplant population and prevention guidelines/regulations and clinical data on toxoplasmosis cases diagnosed during 2010-2014. Serologic pretransplant screening of allo-hematopoietic stem cell donors was performed in 80% of countries, screening of organ donors in 100%. SOT recipients were systematically screened in 6 countries. Targeted anti-Toxoplasma chemoprophylaxis was heterogeneous. A total of 87 toxoplasmosis cases were recorded (58 allo-HSCTs, 29 SOTs). The 6-month survival rate was lower among Toxoplasma-seropositive recipients and among allo-hematopoietic stem cell and liver recipients. Chemoprophylaxis improved outcomes for SOT recipients. Toxoplasmosis remains associated with high mortality rates among transplant recipients. Guidelines are urgently needed to standardize prophylactic regimens and optimize patient management.